Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, 100029, China
NCT Number: NCT07083362
This study adopted a single-center, randomized, double-blind, placebo-controlled, dose-escalation design and was divided into three parts: single-dose dose-escalation (SAD) 、 multiple-dose dose-escalation (MAD)、drug-drug interaction(DDI)
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Beijing, Beijing Municipality, 100029, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subject will receive HRS-8829 at dose level 1.
Subject will receive placebo at dose level 1.
Subject will receive HRS-8829 at dose level 2.
Subject will receive edaravone injection at dose level 5.
Time frame: From ICF signing date to Day8 after single administration
Time frame: From ICF signing date to Day15 after multiple administrations
Time frame: from the date of ICF signing to the 21st day after DDI administration
Time frame: 0 hour to 48 hour after single administration
Time frame: 0 hour to 48 hour after single administration
Time frame: 0 hour to 48 hour after single administration
Time frame: 0 hour to 48 hour after single administration
Time frame: 0 hour to 48 hour after single administration
Time frame: 0 hour to 48 hour after single administration
Time frame: 0 hour to 48 hour after single administration
Time frame: 0 hour to 48 hour after single administration
Time frame: 0 hour to 48 hour after single administration
Time frame: Day1 to Day15 after multiple administrations
Time frame: Day1 to Day15 after multiple administrations
Time frame: Day1 to Day15 after multiple administrations
Time frame: Day1 to Day15 after multiple administrations
Time frame: Day1 to Day15 after multiple administrations
Time frame: Day1 to Day15 after multiple administrations
Time frame: Day1 to Day 16 after DDI study single-dose, plasma administrations
Time frame: Day1 to Day16 after DDI study single-dose, plasma administrations
Time frame: Day1 to Day16 after DDI study single-dose, plasma administrations
Time frame: Day1 to Day16 after DDI study single-dose, plasma administrations
Time frame: Day1 to Day16 after DDI study single-dose, plasma administrations
Time frame: Day1 to Day16 after DDI study single-dose, plasma administrations
Time frame: Day1 to Day16 after DDI study multiple-dose, plasma administrations
Time frame: Day1 to Day16 after DDI study multiple-dose, plasma administrations
Time frame: Day1 to Day16 after DDI study multiple-dose, plasma administrations
Time frame: Day1 to Day16 after DDI study multiple-dose, plasma administrations
Beijing Suncadia Pharmaceuticals Co., Ltd
Industry
Safety, Tolerability and Pharmacokinetic Studies of Single and Multiple Administrations of HRS-8829 in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.